Avanos Medical (NYSE:AVNS) Cut to Buy at Wall Street Zen

Wall Street Zen downgraded shares of Avanos Medical (NYSE:AVNS) from a strong-buy rating to a buy rating in a research report report published on Saturday morning.

Several other analysts have also recently issued reports on AVNS. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Avanos Medical presently has a consensus rating of “Reduce”.

Avanos Medical Trading Down 1.1%

Shares of AVNS opened at $13.95 on Friday. Avanos Medical has a one year low of $9.30 and a one year high of $15.68. The stock has a 50-day moving average price of $13.10 and a 200 day moving average price of $12.14. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15. The company has a market capitalization of $648.49 million, a P/E ratio of -8.83 and a beta of 1.07.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.05. The company had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.Avanos Medical’s revenue for the quarter was up .7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.43 EPS. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Sell-side analysts forecast that Avanos Medical will post 1.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Alpine Global Management LLC acquired a new position in shares of Avanos Medical in the 4th quarter valued at about $177,000. Corient Private Wealth LLC bought a new position in Avanos Medical in the fourth quarter worth about $234,000. Vident Advisory LLC acquired a new position in Avanos Medical in the fourth quarter valued at approximately $585,000. State of Tennessee Department of Treasury grew its holdings in shares of Avanos Medical by 50.0% during the fourth quarter. State of Tennessee Department of Treasury now owns 41,405 shares of the company’s stock valued at $465,000 after purchasing an additional 13,799 shares during the last quarter. Finally, EP Wealth Advisors LLC acquired a new stake in shares of Avanos Medical during the 4th quarter worth approximately $201,000. 95.17% of the stock is currently owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.